Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited · Author: FormBlends Editorial
Key Takeaways
- Whoopi Goldberg confirmed Mounjaro (tirzepatide) use on The View in 2024, naming the medication specifically rather than the more commonly-discussed Ozempic
- Mounjaro is a different molecule from Ozempic; tirzepatide is a dual GLP-1 and GIP receptor agonist made by Eli Lilly
- Her disclosure was open and matter-of-fact, fitting the broader 2024 pattern of celebrity GLP-1 disclosure
- The Mounjaro versus Ozempic distinction is clinically meaningful; the two have different mechanisms, different manufacturers, and different weight-loss profiles
- Her reported loss of approximately two stone (28 pounds) is within typical clinical-trial ranges for tirzepatide
Direct answer
Yes, Whoopi Goldberg has confirmed Mounjaro use. She made the disclosure on The View in 2024. Mounjaro is tirzepatide, made by Eli Lilly, FDA-approved for type 2 diabetes (and approved for obesity under the brand Zepbound). It is a different molecule from Ozempic, with a different mechanism (dual GLP-1 and GIP agonism). Goldberg discussed the medication in the context of her weight management and broader health attention, without making the disclosure into a major statement.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- What Whoopi Goldberg actually said
- The View as a disclosure platform
- Mounjaro versus Ozempic: the clinical distinction
- Tirzepatide's dual mechanism, explained
- The 28-pound loss in clinical-trial context
- The 2024 disclosure wave she contributed to
- Why naming the specific medication matters
- The contrary view: ambiguity in her indication
- Decision framework
- FAQ
- Sources
What Whoopi Goldberg actually said
Goldberg's confirmation came during regular discussion on The View, where she co-hosts and has been candid about her own life across many years. Her core statements:
- She has been on Mounjaro
- She has lost weight she described approximately as "two stone"
- The medication has been part of her broader attention to weight and health management
- She has been open about the use rather than concealing it
The disclosure was woven into broader conversation rather than staged as a major announcement. This pattern is common for The View, where personal disclosures emerge during topical discussion rather than being formal statements.
Her tone has been matter-of-fact rather than evangelical. She has not promoted the medication; she has simply mentioned using it.
The View as a disclosure platform
The View has been an unusually open platform for celebrity GLP-1 disclosure. Both Whoopi Goldberg (Mounjaro) and Tracy Morgan (Ozempic) confirmed use on the show in 2024. Other guests have discussed GLP-1 medications in various contexts.
Why The View?
- Daytime television format encourages personal discussion rather than promotional appearances
- Multiple co-hosts discussing topics in real time creates space for casual disclosure
- The audience demographic (older, predominantly female, daytime viewers) includes many people interested in weight-management discussions
- Whoopi Goldberg's own willingness to discuss the topic created host-level permission
The result has been that The View became a notable site of GLP-1 disclosure in 2024 alongside more formally produced events like Oprah Winfrey's ABC special.
Mounjaro versus Ozempic: the clinical distinction
This distinction is often blurred in popular coverage. The differences:
| Aspect | Mounjaro (tirzepatide) | Ozempic (semaglutide) |
|---|---|---|
| Manufacturer | Eli Lilly | Novo Nordisk |
| Mechanism | Dual GLP-1 and GIP receptor agonist | GLP-1 receptor agonist only |
| FDA approval | Type 2 diabetes (May 2022) | Type 2 diabetes (December 2017) |
| Obesity-indication sibling | Zepbound (approved November 2023) | Wegovy (approved June 2021) |
| Dose range | 2.5 mg to 15 mg weekly | 0.25 mg to 2.0 mg weekly |
| Mean weight loss in obesity trials | 22.5% at 72 weeks (SURMOUNT-1, 15 mg) | 14.9% at 68 weeks (STEP 1) |
| Head-to-head comparison | SURPASS-2 trial: tirzepatide superior to semaglutide for HbA1c reduction in diabetes | - |
The two medications are not interchangeable. They are different molecules with different mechanisms and different manufacturers. Patients who switch between them experience different effects.
When Goldberg specifically named Mounjaro (not Ozempic), she was identifying a distinct medication. This level of specificity is clinically useful and gave her disclosure more medical content than a generic "GLP-1" reference would have.
Tirzepatide's dual mechanism, explained
Tirzepatide is the first medication to combine GLP-1 receptor agonism with GIP (glucose-dependent insulinotropic polypeptide) receptor agonism. The dual mechanism produces stronger effects on:
- Insulin sensitivity (GIP contributes to peripheral glucose uptake)
- Lipid handling (GIP affects adipose tissue lipid storage and release)
- Appetite signaling (both GLP-1 and GIP affect hypothalamic appetite regulation)
The clinical result is greater weight loss in randomized trials. The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) found mean weight loss of 22.5% at the 15 mg dose at 72 weeks, compared to STEP 1's 14.9% mean for semaglutide at 68 weeks. The head-to-head SURPASS-2 trial for diabetes also favored tirzepatide.
This means patients on Mounjaro typically experience larger weight loss than patients on Ozempic, dose for dose. Goldberg's reported 28-pound loss is within the range tirzepatide trials produce for patients in her demographic.
The 28-pound loss in clinical-trial context
Approximately two stone (28 pounds) is a clinically meaningful loss. For a patient in the BMI 30-35 range (a plausible starting point for someone seeking GLP-1 therapy), 28 pounds is approximately 10-12% of body weight.
SURMOUNT-1 trial outcomes by dose:
- 5 mg: ~16% mean loss
- 10 mg: ~21.5% mean loss
- 15 mg: ~22.5% mean loss
Goldberg's 10-12% loss is consistent with a lower-dose maintenance pattern or with partial-protocol use rather than full titration to the top dose. The clinical-trial averages reflect optimized treatment protocols; real-world use often produces somewhat smaller losses because of dose limitations, side-effect tolerability, and adherence variation.
FormBlends clinical observation: patients on tirzepatide who do not titrate to the maximum dose often plateau at 8-12% body weight loss. This is a reasonable and common outcome rather than an underperformance.
The 2024 disclosure wave she contributed to
2024 was the year celebrity GLP-1 disclosure broke open. The cluster of disclosures:
- March 2024: Oprah Winfrey, ABC special "Shame, Blame and the Weight Loss Revolution"
- March-April 2024: Whoopi Goldberg, The View (Mounjaro)
- April 2024: Tracy Morgan, The View (Ozempic)
- Throughout 2024: Various entertainment-figure disclosures across talk shows and interviews
Each disclosure operated in a different register:
- Oprah: public-health framing, weight-stigma critique, broader cultural intervention
- Goldberg: matter-of-fact daytime-TV discussion, embedded in regular show content
- Morgan: comedic-casual, clinical-legitimacy emphasis (his diabetes context)
The combination normalized GLP-1 disclosure across multiple cultural channels. Audiences that found Oprah's framing too earnest could relate to Goldberg's casualness or Morgan's humor. The variety mattered.
Why naming the specific medication matters
Most celebrity GLP-1 disclosures have used "Ozempic" generically, even when the actual medication was different. Goldberg's specific naming of Mounjaro broke that pattern.
The benefits of specificity:
- Audiences learn that GLP-1 is a category, not a brand
- Tirzepatide gets cultural recognition independent of semaglutide
- Clinical accuracy improves when celebrities name the actual medication rather than the generic culturally-dominant brand
- Patients researching options can distinguish between the medications
The cost of generic naming has been real. Many patients ask for "Ozempic" when their clinically appropriate option would be Zepbound or compounded tirzepatide. Goldberg's specificity contributed (modestly) to correcting that confusion.
The contrary view: ambiguity in her indication
Goldberg has not clearly stated whether her Mounjaro use is for diabetes (Mounjaro's FDA-approved indication) or off-label for weight loss. This ambiguity matters.
If she has type 2 diabetes, her Mounjaro use is FDA-indicated and on-label. The weight loss is a documented secondary effect.
If she does not have type 2 diabetes, her use is off-label. The clinically preferred option for weight management in that case would be Zepbound (tirzepatide approved for obesity at FDA-approved doses), not Mounjaro.
Her public statements have referenced "weight management" rather than diabetes management. This phrasing leans toward off-label use, but she has not been explicit. The ambiguity is not a criticism of her; she has no obligation to disclose her indication. It is simply a reading note for audiences interpreting her case.
The reasonable inference: her use is more likely off-label for weight management than indicated for diabetes, but this is an inference rather than a confirmation.
Decision framework
If you have type 2 diabetes and are considering Mounjaro:
- Mounjaro is FDA-approved for your indication
- Tirzepatide outperforms semaglutide for HbA1c reduction in head-to-head trials
- Weight loss is a documented secondary benefit
- Discuss with your diabetes-care provider
If you are considering tirzepatide for weight loss (no diabetes):
- Zepbound is the FDA-approved obesity-indication formulation
- Eligibility is BMI 30+, or BMI 27+ with comorbidities
- Off-label Mounjaro for weight loss diverts supply from diabetes patients
- Compounded tirzepatide is available from 503A pharmacies but is not FDA-approved
If you are comparing tirzepatide and semaglutide:
- Tirzepatide produces larger weight loss on average in clinical trials
- Tirzepatide tends to have more pronounced gastrointestinal side effects
- Cost varies; insurance coverage differs
- The right choice depends on individual response, tolerance, and access
FAQ
Did Whoopi Goldberg confirm Mounjaro use? Yes. Whoopi Goldberg confirmed Mounjaro use during a 2024 appearance on The View. She named the specific medication (Mounjaro, which is tirzepatide for type 2 diabetes), not Ozempic. The distinction matters because Mounjaro and Ozempic are different molecules with different manufacturers and dosing structures.
What is the difference between Mounjaro and Ozempic? Mounjaro is tirzepatide, made by Eli Lilly, FDA-approved for type 2 diabetes. It is a dual GLP-1 and GIP receptor agonist. Ozempic is semaglutide, made by Novo Nordisk, also FDA-approved for type 2 diabetes. It is a GLP-1 receptor agonist only. The two are different molecules, different mechanisms, and different manufacturers. Mounjaro is associated with somewhat larger weight loss in head-to-head trials.
What did Whoopi Goldberg say about Mounjaro? Goldberg discussed Mounjaro openly, mentioning that she had used it as part of her weight management. She has been candid about her overall body changes, attributing them to a combination of medication and dietary attention. The exact quotes vary across appearances; her View discussion was the most-cited confirmation.
How much weight has Whoopi Goldberg lost? She has publicly cited a loss of approximately two stone (about 28 pounds) in conversations about her transformation, though precise current figures vary. Her appearance change has been gradual and sustained across 2023-2024.
Is Whoopi Goldberg's Mounjaro use FDA-approved? Mounjaro is FDA-approved for type 2 diabetes. Tirzepatide is also approved for obesity under the brand name Zepbound (approved November 2023). Whether Goldberg's use is for diabetes management, obesity, or off-label is not entirely clear from her public statements. She has discussed health management broadly without specifying her primary indication.
Why did Whoopi Goldberg's confirmation matter? Her confirmation contributed to the 2024 disclosure wave that included Oprah Winfrey, Tracy Morgan, and others. Her platform (The View) and her cultural standing made the disclosure broadly visible. She also helped distinguish Mounjaro from Ozempic for general audiences who often conflate the medications.
Does Whoopi Goldberg have type 2 diabetes? She has not explicitly confirmed this in detail. She has discussed metabolic health and weight management openly, and she has noted family-history concerns. The specific question of whether she has type 2 diabetes is not clearly answered in her public statements.
What other celebrities confirmed GLP-1 use on The View? Tracy Morgan confirmed Ozempic on The View in April 2024. Various guests have discussed GLP-1 medications in different contexts on the show. The View has been an unusually open platform for celebrity GLP-1 disclosure, reflecting host Whoopi Goldberg's willingness to discuss the medications and the show's daytime-television format.
Should I take Mounjaro because Whoopi takes it? Your decision should be based on your medical situation, not on celebrity examples. If you have type 2 diabetes, discuss Mounjaro with your diabetes-care provider. If you are seeking weight management, the FDA-approved option is Zepbound; eligibility requires BMI 30+ or BMI 27+ with comorbidities.
What dose of Mounjaro does Whoopi Goldberg take? She has not specified the dose. Mounjaro is titrated from 2.5 mg up to 15 mg weekly. Her reported loss of about 28 pounds is consistent with a moderate dose (5-10 mg) rather than the maximum.
Sources
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM. 2022. (SURMOUNT-1)
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM. 2021. (STEP 1)
- Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. NEJM. 2021. (SURPASS-2)
- FDA Drug Approvals Database. Mounjaro approval, May 2022.
- FDA Drug Approvals Database. Zepbound approval, November 2023.
- FDA Drug Approvals Database. Ozempic approval, December 2017; Wegovy approval, June 2021.
- The View. Whoopi Goldberg Mounjaro discussion, 2024.
- The View. Tracy Morgan Ozempic confirmation, April 2024.
- American Diabetes Association. Standards of Care in Diabetes 2024.
- American Association of Clinical Endocrinologists. Clinical Practice Guidelines for Obesity Management. 2022.
- Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction. JAMA. 2024. (SURMOUNT-4)
- Pearl RL et al. Weight Bias and Stigma: Public Health Implications. Obesity. 2023.
Footer disclaimers
Platform Disclaimer. FormBlends operates as a digital health platform connecting eligible patients with U.S.-licensed providers and pharmacies. We do not prescribe or dispense medication directly. Independent licensed providers make all clinical decisions.
Compounded Medication Notice. Compounded tirzepatide is not the same as brand Mounjaro or Zepbound. Compounded tirzepatide is produced by state-licensed 503A pharmacies in response to individual prescriptions and has not undergone the FDA new-drug approval pathway. It is not interchangeable with FDA-approved tirzepatide formulations.
Results Disclaimer. Whoopi Goldberg's reported weight-loss outcome reflects her individual case. Clinical-trial averages (SURMOUNT-1 mean of 22.5% at the 15 mg dose) describe study populations under controlled conditions and do not predict outcomes for individual patients.
Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. The View is a registered trademark of ABC / Disney. FormBlends is not affiliated with, endorsed by, or sponsored by Whoopi Goldberg, The View, ABC, Eli Lilly, Novo Nordisk, or any other party referenced in this article.